Current Report Filing (8-k)
February 26 2014 - 4:14PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 26, 2014
INOVIO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-14888 |
|
33-0969592 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
1787 Sentry Parkway West
Building 18, Suite 400
Blue Bell, Pennsylvania |
|
19422 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (267) 440-4200
N/A
(Former name or
former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Inovio Pharmaceuticals, Inc. (the Company) is filing this
Form 8-K current report to provide certain information as an update to the information provided in the Companys previous periodic filings with the Securities and Exchange Commission (the SEC) in order to reflect recent business
developments. A summary description of the Companys business is attached hereto as Exhibits 99.1 and is incorporated herein by reference. This Form 8-K, including the exhibits hereto, should be read in conjunction with the Companys Form
10-K annual report for the year ended December 31, 2012, the Companys Form 10-Q quarterly reports for the quarters ended March 31, 2013, June 30, 2013 and September 30, 2013 and the Companys Form 8-K current
reports.
On February 26, 2014, the Company issued a press release announcing its intention to offer and sell shares of its common
stock in an underwritten public offering, subject to market conditions and other factors, pursuant to the Companys effective Registration Statement on Form S-3 (File No. 333-193698). The full text of the press release issued in connection
with the announcement is attached to this Form 8-K as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01. |
Financial Statements and Exhibits. |
|
|
|
Exhibit No. |
|
Exhibit Description |
|
|
99.1 |
|
Updated Summary Business Description |
|
|
99.2 |
|
Inovio Pharmaceuticals, Inc. Press Release dated February 26, 2014 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
INOVIO PHARMACEUTICALS, INC. |
|
|
By: |
|
/s/ Peter Kies |
|
|
Peter Kies, |
|
|
Chief Financial Officer |
Date: February 26, 2014
-3-
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Sep 2023 to Sep 2024